The American Diabetes Association (ADA) and European Association for the study of diabetes recommend oral hypoglycemic agents (OHAs); biguanides (metformin) as first-line treatment while sulphonylureas, meglitinides (glinides), α-glucosidase inhibitors, dipeptidyl peptidase-IV (DPP-4) inhibitors, glucagon-like polypeptide-1 (GLP-1), sodium-glucose co-transporter-2 (SGLT2) inhibitors, amylin mimetics, dopamine-2 agonist, and insulin analogues as a second line treatment [6, 7]. This evidence concerns the gene SLC5A2 and diabetes mellitus.